Contributions
Abstract: P663
Type: Poster
Abstract Category: Therapy - disease modifying - Immunomodulation/Immunosuppression
Background: The role of nitric oxide and its reactive derivatives: nitrate and nitrite (NOx) is well-known in the pathogenesis of multiple sclerosis (MS). MS is an inflammatory disease while NOx seems to be important in coordinating inflammatory response.
Goals: The purpose of the study was to assess serum nitrogen species and inflammatory parameters in relapsing-remitting MS (RRMS) patients and to compare effectiveness of the various types of disease modifying therapy (DMT) in reduction of nitric oxide and inflammatory biomarkers levels.
Methods: 63 RRMS patients and 10 healthy subjects (HS) were included in the study.
Serum NOx, C-Reactive Protein (CRP) and interleukin 1 beta (IL-1β/IL-1F2) concentrations were evaluated. Annual Gadolinum (AGd+) -and T2 enhanced lesions (AT2) were obtained in magnetic resonance imaging (MRI).
Patients were divided into 2 groups: LI: 44 patients whose received the first line of DMT (interferons beta 1a,-1b or glatiramer acetate) and LII: 19 patients treated with the second line of DMT (natalizumab or fingolimod).
NOx, CRP, IL-1β/IL-1F2, Expanded Disability Status Scale (EDSS), annual relapse rate (ARR) and MRI lesions were compared between the groups.
Results: Higher NOx levels were noted in LI in comparison to the LII and HS (2.04±0.70, 1.57±0.31, 1.50±0.16 µM, p=0.03, respectively) without significant differences in CRP (2.13±2.47, 1.49±2.05, 1.19±0.55 mg/l, p=0.52, respectively) and IL-1β/IL-1F2 (1.51±0.46, 1.76±0.92, 1.64±0.47 pg/mL, p=0.47, respectively). LI and LII did not differ in EDSS (2.48±0.48, 2.97±1.17, p=0.10, respectively), AGd+ (2.39±15.2, 0.53±1.43, p=0.60, respectively), AT2 (0.09±0.29, 0.21±0.54, p=0.42, respectively), ARR (0.36±0.57, 0.32±0.67, p=0.51, respectively).
There was observed negative correlation between serum NOx level and time of MS in whole studied population (R= -0.3046, p< 0.05) which was not confirmed between NOx and EDSS (R= -0.19, p>0.05) or between NOx and AGd+ (R= -0.22, p>0.05), AT2 (R= -0.05, p>0.05) and ARR (R= 0.007, p>0.05).
Conclusions: Only serum NOx concentration could reveal potentially efficacy of DMT with better reduction of NOx level by the second line agents of DMT. NOx serum concentration seems to be a biomarker of MS duration.
Disclosure: Natalia Niedziela: nothing to disclose
Monika Adamczyk-Sowa: nothing to disclose
Jacek Niedziela: nothing to disclose
Bogdan Mazur: nothing to disclose
Ewa Kluczewska: nothing to disclose
Paweł Sowa: nothing to disclose
Mariusz Gasior: nothing to disclose
Abstract: P663
Type: Poster
Abstract Category: Therapy - disease modifying - Immunomodulation/Immunosuppression
Background: The role of nitric oxide and its reactive derivatives: nitrate and nitrite (NOx) is well-known in the pathogenesis of multiple sclerosis (MS). MS is an inflammatory disease while NOx seems to be important in coordinating inflammatory response.
Goals: The purpose of the study was to assess serum nitrogen species and inflammatory parameters in relapsing-remitting MS (RRMS) patients and to compare effectiveness of the various types of disease modifying therapy (DMT) in reduction of nitric oxide and inflammatory biomarkers levels.
Methods: 63 RRMS patients and 10 healthy subjects (HS) were included in the study.
Serum NOx, C-Reactive Protein (CRP) and interleukin 1 beta (IL-1β/IL-1F2) concentrations were evaluated. Annual Gadolinum (AGd+) -and T2 enhanced lesions (AT2) were obtained in magnetic resonance imaging (MRI).
Patients were divided into 2 groups: LI: 44 patients whose received the first line of DMT (interferons beta 1a,-1b or glatiramer acetate) and LII: 19 patients treated with the second line of DMT (natalizumab or fingolimod).
NOx, CRP, IL-1β/IL-1F2, Expanded Disability Status Scale (EDSS), annual relapse rate (ARR) and MRI lesions were compared between the groups.
Results: Higher NOx levels were noted in LI in comparison to the LII and HS (2.04±0.70, 1.57±0.31, 1.50±0.16 µM, p=0.03, respectively) without significant differences in CRP (2.13±2.47, 1.49±2.05, 1.19±0.55 mg/l, p=0.52, respectively) and IL-1β/IL-1F2 (1.51±0.46, 1.76±0.92, 1.64±0.47 pg/mL, p=0.47, respectively). LI and LII did not differ in EDSS (2.48±0.48, 2.97±1.17, p=0.10, respectively), AGd+ (2.39±15.2, 0.53±1.43, p=0.60, respectively), AT2 (0.09±0.29, 0.21±0.54, p=0.42, respectively), ARR (0.36±0.57, 0.32±0.67, p=0.51, respectively).
There was observed negative correlation between serum NOx level and time of MS in whole studied population (R= -0.3046, p< 0.05) which was not confirmed between NOx and EDSS (R= -0.19, p>0.05) or between NOx and AGd+ (R= -0.22, p>0.05), AT2 (R= -0.05, p>0.05) and ARR (R= 0.007, p>0.05).
Conclusions: Only serum NOx concentration could reveal potentially efficacy of DMT with better reduction of NOx level by the second line agents of DMT. NOx serum concentration seems to be a biomarker of MS duration.
Disclosure: Natalia Niedziela: nothing to disclose
Monika Adamczyk-Sowa: nothing to disclose
Jacek Niedziela: nothing to disclose
Bogdan Mazur: nothing to disclose
Ewa Kluczewska: nothing to disclose
Paweł Sowa: nothing to disclose
Mariusz Gasior: nothing to disclose